Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for T-cell/histiocyte-rich large B-cell lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
The line between this disease and the diffuse pattern of nodular lymphocyte predominant Hodgkin lymphoma cannot always be drawn, and the two are treated differently.
The cancer cells of the two conditions are not distinguishable by gene expression. What differs is the immune cells around them, and nobody knows why the same tumour cell produces an indolent disease in one person and an aggressive one in another.
No trial has been confined to this entity, so the treatment is borrowed from diffuse large B-cell lymphoma on the strength of the shared surface marker.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
Both errors are common and they point in opposite directions. Called inflammatory, the lymphoma is missed, because the tumour cells are a small minority and the tissue looks reactive. Called nodular lymphocyte predominant Hodgkin lymphoma, an aggressive disease is treated as an indolent one. WHO-HAEM5 states that a clear distinction from the diffuse pattern of that disease may not be possible in some cases, and that small biopsies are the hardest. A generous biopsy, read by a haematopathologist, with the surrounding cells examined as carefully as the tumour cells, is the answer the classification gives.
WHO-HAEM5 tabulates six growth patterns of nodular lymphocyte predominant Hodgkin lymphoma and names the diffuse one after this disease; the International Consensus Classification renamed that disease a B-cell lymphoma partly on the strength of the relationship.
Profiling the microdissected tumour cells of nodular lymphocyte predominant Hodgkin lymphoma, its diffuse pattern and this disease found no consistent differences between them; the differences were in the surrounding T cells and histiocytes.
A review of 30 cases separated three appearances of the large cells and showed nuclear BCL6 in 26 of 29, placing the tumour cell in the germinal centre.